OSAKA, Japan and CAMBRIDGE, Massachusetts
,
February 3, 2022
(press release)
–
Takeda (TSE:4502/NYSE:TAK) today announced changes to its executive leadership team to continue driving long-term growth in a highly competitive and dynamic global marketplace. The leadership changes, unless otherwise noted, will be effective at the start of Takeda’s fiscal year 2022 (April 1, 2022) and these executives will report to President and CEO Christophe Weber: Gabriele Ricci, who formerly served as Head of IT for the Plasma-Derived Therapies (PDT) Business Unit has been appointed Takeda’s Chief Data and Technology Officer, effective February 1, 2022. In this role, Gabriele will lead the critical transformation of the company’s Data, Digital and Technology division. Elevating and evolving the company’s existing IT function demonstrates the company’s commitment to creating an industry-leading data and technology approach to ultimately help better deliver life-transforming treatments to patients and society. “My executive leadership team has been instrumental in helping to shape Takeda into a global, values-based biopharmaceutical company that delivers transformational medicine to patients around the world. Our strategy is working, and we continue to gain momentum – with competitive scale, a global footprint and a diverse pipeline with approximately 40 new molecular entities in clinical development,” said Christophe Weber, president and CEO, Takeda. “We are looking to the future, with clear goals in mind, including the opportunity to reinforce our global launch capabilities and harness data and digital to revolutionize the patient experience. This is the team that will help take us to the next level and ensure that we continue to grow and evolve.” In addition, Takeda will expand the roles of other executive team members, including Lauren Duprey, Chief Human Resource Officer, to further focus on employee well-being; Takako Ohyabu, Chief Global Corporate Affairs and Sustainability Officer, to accelerate delivering against our purpose-led sustainability agenda; and Mwana Lugogo, Global Ethics and Compliance, to include data privacy. Takeda will also continue to have a focus on and commitment to its Oncology Business Unit and Japan Business Unit, along with its other critical functional areas such as Research and Development, Finance, Business Development, Human Resources, Quality, Ethics & Compliance, Legal, Global Corporate Affairs, Corporate Strategy and Manufacturing with executive leadership of these areas continuing to report to Mr. Weber. About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.